Literature DB >> 21243069

Therapeutics for Circadian Rhythm Sleep Disorders.

Ehren R Dodson, Phyllis C Zee.   

Abstract

The sleep-wake cycle is regulated by the interaction of endogenous circadian and homeostatic processes. The circadian system provides timing information for most physiological rhythms, including the sleep and wake cycle. In addition, the central circadian clock located in the suprachiasmatic nucleus of the hypothalamus has been shown to promote alertness during the day. Circadian rhythm sleep disorders arise when there is a misalignment between the timing of the endogenous circadian rhythms and the external environment or when there is dysfunction of the circadian clock or its entrainment pathways. The primary synchronizing agents of the circadian system are light and melatonin. Light is the strongest entraining agent of circadian rhythms and timed exposure to bright light is often used in the treatment of circadian rhythm sleep disorders. In addition, timed administration of melatonin, either alone or in combination with light therapy has been shown to be useful in the treatment of the following circadian rhythm sleep disorders: delayed sleep phase, advanced sleep phase, free-running, irregular sleep wake, jet lag and shift work.

Entities:  

Year:  2010        PMID: 21243069      PMCID: PMC3020104          DOI: 10.1016/j.jsmc.2010.08.001

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN: 1556-407X


  119 in total

1.  Familial advanced sleep phase syndrome.

Authors:  K J Reid; A M Chang; M L Dubocovich; F W Turek; J S Takahashi; P C Zee
Journal:  Arch Neurol       Date:  2001-07

2.  A multicenter study of sleep-wake rhythm disorders: therapeutic effects of vitamin B12, bright light therapy, chronotherapy and hypnotics.

Authors:  H Yamadera; K Takahashi; M Okawa
Journal:  Psychiatry Clin Neurosci       Date:  1996-08       Impact factor: 5.188

3.  Therapeutic entrainment of circadian rhythm disorder by melatonin in a non-blind patient.

Authors:  M Siebler; H Steinmetz; H J Freund
Journal:  J Neurol       Date:  1998 Jun-Jul       Impact factor: 4.849

4.  Evaluating the role of melatonin in the long-term treatment of delayed sleep phase syndrome (DSPS).

Authors:  Y Dagan; I Yovel; D Hallis; M Eisenstein; I Raichik
Journal:  Chronobiol Int       Date:  1998-03       Impact factor: 2.877

5.  Delayed sleep phase syndrome response to melatonin.

Authors:  M Dahlitz; B Alvarez; J Vignau; J English; J Arendt; J D Parkes
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

6.  Trials of bright light exposure and melatonin administration in a patient with non-24 hour sleep-wake syndrome.

Authors:  T Hayakawa; Y Kamei; J Urata; K Shibui; S Ozaki; M Uchiyama; M Okawa
Journal:  Psychiatry Clin Neurosci       Date:  1998-04       Impact factor: 5.188

7.  Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study.

Authors:  Charles A Czeisler; James K Walsh; Keith A Wesnes; Sanjay Arora; Thomas Roth
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 8.  Delayed sleep phase syndrome: a review of its clinical aspects.

Authors:  Q R Regestein; T H Monk
Journal:  Am J Psychiatry       Date:  1995-04       Impact factor: 18.112

9.  Relationship between melatonin rhythms and visual loss in the blind.

Authors:  S W Lockley; D J Skene; J Arendt; H Tabandeh; A C Bird; R Defrance
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

Review 10.  Melatonin for the prevention and treatment of jet lag.

Authors:  A Herxheimer; K J Petrie
Journal:  Cochrane Database Syst Rev       Date:  2002
View more
  25 in total

1.  [The current state of research in bright light therapy].

Authors:  Daniela Bassa; Markus Canazei; Hartmann Hinterhuber; Elisabeth M Weiss
Journal:  Neuropsychiatr       Date:  2013-06-21

2.  Circadian Rhythmicity as a Predictor of Quality of Life in Allogeneic Hematopoietic Cell Transplant Patients.

Authors:  Aasha I Hoogland; Hailey W Bulls; Brian D Gonzalez; Brent J Small; Lianqi Liu; Joseph Pidala; Heather S L Jim; Asmita Mishra
Journal:  J Pain Symptom Manage       Date:  2019-01-31       Impact factor: 3.612

Review 3.  Tasimelteon: first global approval.

Authors:  Sohita Dhillon; Madeleine Clarke
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

4.  Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems.

Authors:  Ozlem Gun Eryilmaz; Aysun Devran; Esma Sarikaya; Fatma Nur Aksakal; Leyla Mollamahmutoğlu; Nedim Cicek
Journal:  J Assist Reprod Genet       Date:  2011-07-12       Impact factor: 3.412

Review 5.  The Impact of Sleep and Circadian Disorders on Physician Burnout.

Authors:  Nancy H Stewart; Vineet M Arora
Journal:  Chest       Date:  2019-07-25       Impact factor: 9.410

Review 6.  Genetic insights on sleep schedules: this time, it's PERsonal.

Authors:  S Y Christin Chong; Louis J Ptáček; Ying-Hui Fu
Journal:  Trends Genet       Date:  2012-08-28       Impact factor: 11.639

Review 7.  Circadian rhythm abnormalities.

Authors:  Phyllis C Zee; Hrayr Attarian; Aleksandar Videnovic
Journal:  Continuum (Minneap Minn)       Date:  2013-02

8.  Non-surgical periodontal therapy influences salivary melatonin levels.

Authors:  Kristina Bertl; Angelika Schoiber; Hady Haririan; Markus Laky; Irene Steiner; W D Rausch; Oleh Andrukhov; Xiaohui Rausch-Fan
Journal:  Clin Oral Investig       Date:  2012-07-31       Impact factor: 3.573

Review 9.  Sick and tired: how molecular regulators of human sleep schedules and duration impact immune function.

Authors:  Philip A Kurien; S Y Christin Chong; Louis J Ptáček; Ying-Hui Fu
Journal:  Curr Opin Neurobiol       Date:  2013-05-20       Impact factor: 6.627

Review 10.  Recommendations of the Sleep Study Group of the Italian Dementia Research Association (SINDem) on clinical assessment and management of sleep disorders in individuals with mild cognitive impairment and dementia: a clinical review.

Authors:  B Guarnieri; M Musicco; P Caffarra; F Adorni; I Appollonio; D Arnaldi; A Bartoli; E Bonanni; U Bonuccelli; C Caltagirone; G Cerroni; L Concari; F I I Cosentino; S Fermi; R Ferri; G Gelosa; G Lombardi; S Mearelli; F Nobili; S Passero; R Perri; R Rocchi; P Sucapane; G Tognoni; S Zabberoni; S Sorbi
Journal:  Neurol Sci       Date:  2014-07-19       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.